Ocular Therapeutix (OCUL) Current Assets (2013 - 2026)

Ocular Therapeutix's Current Assets history runs 14 years deep, the most recent figure standing at $706.0 million for Q1 2026.

• In Q1 2026, Current Assets rose 82.1% year-over-year to $706.0 million; the TTM figure through Mar 2026 stood at $706.0 million (up 82.1% YoY), while the FY2025 annual figure was $782.1 million, up 77.36% from the prior year.
• Current Assets was $706.0 million for Q1 2026 at Ocular Therapeutix, down from $782.1 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $782.1 million in Q4 2025 to a low of $100.7 million in Q2 2023.
• Historically, Current Assets has averaged $342.4 million across 5 years, with a median of $387.0 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Current Assets slumped 38.64% in 2023, then jumped 395.06% in 2024.
• A 5-year view of Current Assets shows it stood at $129.6 million in 2022, then surged by 79.16% to $232.2 million in 2023, then soared by 89.89% to $441.0 million in 2024, then surged by 77.36% to $782.1 million in 2025, then retreated by 9.73% to $706.0 million in 2026.
• The last three Current Assets figures came in at $706.0 million (Q1 2026), $782.1 million (Q4 2025), and $387.0 million (Q3 2025), per Business Quant data.